W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma
Mebea Aklilu,Walter M. Stadler,Mary A. Markiewicz,N. J. Vogelzang,Michael A. Mahowald,M. Johnson,Thomas F. Gajewski +6 more
TL;DR: The results suggest that depletion of circulating B cells with rituximab does not increase the response rate, alter the toxicity profile or change the biological activity in response to low-dose IL-2 in patients with RCC or melanoma.
Journal ArticleDOI
Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.
Hedy L. Kindler,Nicholas P. Campbell,Kristen Wroblewski,Robert G. Maki,D. R. D'Adamo,Warren Chow,David R. Gandara,C. R. Antonescu,Walter M. Stadler,E. E. Vokes +9 more
TL;DR: SOR has definite activity in IM/SU-resistant GIST, with a disease control rate of 68%.
Journal ArticleDOI
Evaluation of the Prostate Bed for Local Recurrence After Radical Prostatectomy Using Endorectal Magnetic Resonance Imaging
Stanley L. Liauw,Sean P. Pitroda,Scott E. Eggener,Walter M. Stadler,Charles A. Pelizzari,Michael W. Vannier,A. Oto +6 more
TL;DR: Endorectal MRI can define areas of local recurrence after RP in a minority of men without clinical evidence of disease, with yield related to PSA, and it is necessary to determine whether eMRI can improve patient selection and success of salvage RT.
Journal ArticleDOI
Development of target-based antineoplastic agents.
Walter M. Stadler,Mark J. Ratain +1 more
TL;DR: Wepropose clinical trial designs, including a randomizeddiscontinuation design during phase II evaluation, that may beparticularly useful for cytostatic antineoplastic agents.
Journal ArticleDOI
Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
Timothy Eisen,Ronald M. Bukowski,Michael Staehler,C. Szczylik,Stéphane Oudard,Walter M. Stadler,Brian Schwartz,Ronit Simantov,M. Shan,Bernard Escudier +9 more
TL;DR: A prospectively planned interim OS analysis reflecting impact of crossover of placebo patients is presented and supports independently reviewed doubling of PFS to 24 weeks in RCC patients receiving sorafenib compared with placebo.